Measurement of Serum YKL 40 Level in Patients with Vitiligo and Its Relation with Disease Severity | ||||
| Egyptian Journal of Medical Research | ||||
| Volume 4, Issue 4, October 2023, Page 156-168 PDF (564.45 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejmr.2023.187511.1321 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Hanan Abdelrazik kamel1; Walaa Alaa El-deen Mohamed Abo El-Wafa  1; Abdel Aziz Ibrahim Al-Taweel1; Hanan Hosni Moawad 2
| ||||
| 1Dermatology and Andrology Department, Faculty of Medicine, Beni Suef University | ||||
| 2Clinical and Chemical Pathology Department, Faculty of Medicine, Beni Suef University | ||||
| Abstract | ||||
| Background: The selective destruction of melanocytes characterizes the persistent skin disorder known as vitiligo. A small percentage of the global population (0.5–2.0%) suffers from vitiligo, an acquired depigmentation disorder. Since it typically shows up on the face and other noticeable areas, it could be psychologically upsetting. One of the conserved families of mammalian chitinases is YKL-40, or chitinase-3-like protein 1. Aim of the Work: This study was set out to determine how vitiligo patients' serum levels of the inflammatory biomarker YKL-40 (CH3L1) varied with disease severity. Patients and Methods: Two groups were involved in this study: Forty vitiligo patients comprised the first group. They ranged in age from eighteen to fifty-nine and included both men and women. Forty healthy people served as control cases in the second group. They ranged in age from sixteen to fifty years old and included both boys and ladies. Results: As none of the vitiligo cases we looked at had any comorbidities, including skin or systemic diseases, our results suggest that YKL-40 may play a role in the etiology of vitiligo disease and demonstrate the clear elevation of this parameter in vitiligo patients. While a greater YKL-40 level may indicate systemic inflammation in vitiligo patients, it does not appear that YKL-40 concentration directly correlates with the degree of skin alterations. Additionally, YKL-40 seems to be a highly sensitive indicator of illness in vitiligo patients. After calculating the ideal serum YKL-40 cut-off value using the ROC curve, we found that this parameter was 100% sensitive and specific within our patient group. Conclusion: The fact that YKL-40 levels are higher in vitiligo patients raises the possibility that it plays a role in the onset of the disease. | ||||
| Keywords | ||||
| Serum YKL 40 Level; Vitiligo; Chitinase-3-like protein 1 | ||||
| References | ||||
|
1- Allam M, Riad H (2013): Concise review of recent studies in vitiligo. Qatar Med J. (2):1-19.
2- Zhang L, Chen S, Kang Y, et al. (2019): Association of Clinical Markers with Disease Progression in Patients with Vitiligo from China. JAMA Dermatol.; 156(3):288-295.
3- Dwivedi, M., Naresh, L., Laddha, C., et al. (2015). Vitiligo A Complex Autoimmune Skin Depigmenting Disease, Autoimmunity - Pathogenesis, Clinical Aspects and Therapy of Specific Autoimmune Diseases; 153.
4- van Geel, N., Grine, L., De Wispelaere, P., et al. (2019): Clinical visible signs of disease activity in vitiligo: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. (9):1667-1675.
5- Salomon, J., Matusiak, Ł., Nowicka-Suszko, D., Szepietowski, J.C. (2017). Chitinase-3-Like Protein 1 (YKL-40) Is a New Biomarker of Inflammation in Psoriasis. Mediators Inflamm.; 2017:9538451.
6- Zhao, T., Su, Z., Li, Y., Zhang, X., You, Q. J. S. T., & Therapy, T. (2020). Chitinase-3 like-protein-1 function and its role in diseases. Signal Transduction and Targeted Therapy, 5(1), 1-20.
7- Feily, A., Baktash, D. and Mohebbipour, A. (2013). Potential advantages of simvastatin as a novel anti-vitiligo arsenal. European Review for Medical and Pharmacological Sciences, 17(14), 1982-1983.
8- Taieb AV, Alomar A, Böhm M, et al. (2013): Guidelines for the management of vitiligo: The European Dermatology Forum consensus. Br J Dermatol; 168 (1):5-19.
9- Sidiropoulou, P., Sgouros, D., & Rigopoulos, D. (2019). Skin disorders causing post-inflammatory hypopigmentation. Hypopigmentation, 127-132.
10- Inoue, S., Katayama, I., Suzuki, T., Tanemura, A., Ito, S., Abe, Y., & Matsunaga, K. (2021). Rhododendrol‐induced leukoderma update II: Pathophysiology, mechanisms, risk evaluation, and possible mechanism-based treatments in comparison with vitiligo. The Journal of Dermatology, 48(7), 969-978.
11- Salomon, J., Matusiak, Ł., Nowicka-Suszko, D., & Szepietowski, J. C. (2017a). Chitinase-3-Like Protein 1 (YKL-40) Is a New Biomarker of Inflammation in Psoriasis. Mediators of Inflammation, 2017, 1–4.
12- Salomon, J., Matusiak, Ł., Nowicka-Suszko, D., & Szepietowski, J. C. (2017-b). Chitinase-3-like protein 1 (ykl-40) reflects the severity of symptoms in atopic dermatitis. Journal of immunology research, 2017.
13- Elhabak, D. M., & Halim, W. A. A. (2020). YKL-40 a sensitive biomarker for early androgenetic alopecia and early hidden metabolic syndrome. International journal of trichology, 12(2), 49.
14- Sh, A. R., Ms, H., Na, S., & Mm, A. M. (2022). Serum level of YKL-40, C-reactive protein and ESR in Patients with Vitiligo. Benha Journal of Applied Sciences, 7(3), 1-7.
15- Jin, Y., Roberts, G. H., Ferrara, T. M., Ben, S., van Geel, N., Wolkerstorfer, A., Spritz, R. A. (2019). Early-onset autoimmune vitiligo associated with an enhancer variant haplotype that upregulates class II HLA expression. Nature communications, 10(1), 1-10.
16- Poudyal, Y., Jha, C. B., & Parajuli, N. (2021). Gender Differences in Clinical and Epidemiological Profile of Adult Patients with Vitiligo. Journal of Universal College of Medical Sciences, 9(01), 24-27.
17- Seneschal, J., Boniface, K., D'Arino, A., & Picardo, M. (2021). An update on Vitiligo pathogenesis. Pigment cell & melanoma research, 34(2), 236-243.
18- Hemida, N. G. A. E., El-Rifaie, A. E. A. E., Rashed, L. A., & Kamel, H. A. E. (2022). Measurement of Serum Chitinase 3 Like 1 Protien in Vitiligo Patients. Egyptian Journal of Medical Research, 3(1), 120-130.
19- Migayron, L., Boniface, K., & Seneschal, J. (2020). Vitiligo, from physiopathology to emerging treatments: a review. Dermatology and Therapy, 10(6), 1185-1198.
20- Dahir, A. M., & Thomsen, S. F. (2018). Comorbidities in vitiligo: comprehensive review. International journal of dermatology, 57(10), 1157-1164.
21- Ezzat SM, Ibrahim HM, Mohamed NA, Saleh MA, El-Tawdi AH. Serum YKL-40 level in vitiligo patients: a possible biomarker for disease activity. Journal of the European Academy of Dermatology and Venereology. 2021;35(4):e235-e238. | ||||
|
Statistics Article View: 65 PDF Download: 16 |
||||
